Skip to content
‹ Back to IndustriesSciences

Advocating for the Scientific Community Through Media

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.   Looking at all aspects of the world of space and science is the crux of Space to Grow. It’s time to look at the human…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · AstroscaleCharity Weeden PodcastChris Blackerby PodcastEducation
Share

Key takeaways

01

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

02

Looking at all aspects of the world of space and science is the crux of Space to Grow.

03

It’s time to look at the human…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

Looking at all aspects of the world of space and science is the crux of Space to Grow. It’s time to look at the human and storytelling aspect of science and space. Hosts Chris Blackerby and Charity Weeden of Astroscale welcomed MIT Engineer and Emmy-nominated science TV host Emily Calandrelli to the podcast. Calandrelli is a prominent member of the science communications ecosystem and shared her own story and insights on storytelling in science.

Becoming an engineer wasn’t a lifelong dream for Calandrelli—her drive was purely practical until discovering the technology and policy program in grad school at MIT. “It was looking at science and technology through a policy lens and asking about if it’s ethical, the role of government, and keeping the public safe. I thought these were fascinating questions,” she said.

That experience shifted her career to be more policy and communications driven. She intended to work in DC but got a call from a production company asking her if she wanted to host a TV show about space.

Years later, she’s a strong voice for the scientific community and advocates for people with all different talents to get involved in the space industry. “There are other ways to get involved in space outside of STEM,” she added.

Those types of roles are now trying to spread scientific literary and combat misinformation. Calandrelli focuses her approach on the human side of the story. She explained, “Going to the real human emotions attached to the story matters. You can frame an argument based on what the audience cares about and find simple, creative ways to explain science.”

Science is complex and uncertain, especially the coronavirus. In communicating a difficult and uncertain event, Calandrelli sees that science communication is challenging. “Everyone’s learning how to communicate this uncertainty, but there’s a lot of false information out there. It’s important to learn from the right sources,” she said.

Listen to Previous Episodes Here!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Crown Bioscience Appoints Guy Sheets as Senior Vice President, Commercial

Crown Bioscience appointed Guy Sheets as Senior Vice President, Commercial, bringing over 30 years of pharma and life sciences experience to lead the CRO's global commercial strategy. Sheets previously held senior commercial roles at QPS Holdings, CenExel, SGS Health Sciences, Lonza, and Thermo Fisher Scientific.

  • 01Guy Sheets brings 30+ years of commercial leadership across pharma, biotech, and life sciences, most recently as VP, Head of Global Business Development at QPS Holdings
  • 02Crown Bioscience operates 9 facilities across the US, Europe, and APAC with a portfolio of 2,800+ patient-derived xenograft models and 1,000+ tumor organoid models across 35 cancer indications
  • 03Sheets will lead Crown Bioscience’s global commercial strategy to drive growth, expand market presence, and strengthen client partnerships

Nov 3, 2026

Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Merck has invested more than €300 million in a new bioprocessing production center in Daejeon, South Korea. It is the largest life science investment Merck has made in the region to date. The 44,500-square-meter facility makes cell culture media, process liquids and sterile sampling products to support biologics manufacturing from development through commercial supply.

  • 01A single Asia-Pacific site now supplies both small custom pre-GMP media and commercial-scale media, so a regional biologics program could scale without switching to a source outside the region.
  • 02Daejeon supplies cell culture media, process liquids, ready-to-use cleaning-in-place solutions and sterile sampling products.
  • 03The useful supplier question has moved past whether Merck has an Asia-Pacific plant: ask which product lines ship from Daejeon and what batch traceability data customers can see.

Nov 3, 2026

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox projects the quantum cascade laser market to grow 8% to 12% a year through 2035, linking the outlook to faster adoption of mid-infrared spectroscopy in process control, environmental monitoring and pharmaceutical QA. It says QCLs win on high spectral brightness and room-temperature operation in compact form factors, and that the installed base of analytical instruments is growing.

  • 01Roughly one in three quantum cascade lasers shipped in 2030 is projected to replace equipment already in service, so maintenance calendars will set a growing share of demand.
  • 02For a plant or QA lab running QCL-based analyzers, the useful question is which laser maker sits inside each instrument and whether a second source exists.
  • 03Analyzers bought on a three-to-five-year cycle in 2026 come due between 2029 and 2031. Those years will show whether the forecast replacement wave turns up in real orders.

Oct 26, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512